論文

査読有り
2015年10月

Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor

INTERNATIONAL JOURNAL OF UROLOGY
  • Takahiro Kojima
  • ,
  • Koji Kawai
  • ,
  • Kunihiko Tsuchiya
  • ,
  • Takashige Abe
  • ,
  • Nobuo Shinohara
  • ,
  • Toshiaki Tanaka
  • ,
  • Naoya Masumori
  • ,
  • Shigeyuki Yamada
  • ,
  • Yoichi Arai
  • ,
  • Shintaro Narita
  • ,
  • Norihiko Tsuchiya
  • ,
  • Tomonori Habuchi
  • ,
  • Hiroyuki Nishiyama

22
10
開始ページ
923
終了ページ
927
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/iju.12844
出版者・発行元
WILEY-BLACKWELL

ObjectivesTo clarify the significance of the International Germ Cell Cancer Collaborative Group classification in the 2000s, especially in intermediate- and poor-prognosis testicular germ cell tumor in Japan.
MethodsWe retrospectively analyzed 117 patients with intermediate- and poor-prognosis testicular non-seminomatous germ cell tumor treated at five university hospitals in Japan between 2000 and 2010. Data collected included age, levels of tumor markers, spread to non-pulmonary visceral metastases, treatment details and survival.
ResultsThe median follow-up period of all patients was 57months. A total of 50 patients (43%) were classified as having intermediate prognosis, and 67 patients (57%) as poor prognosis according to the International Germ Cell Cancer Collaborative Group classification. As first-line chemotherapy, 92 patients (79%) received bleomycin, etoposide and cisplatin. Of all patients, 74 patients (63%) received second-line chemotherapy. The most commonly used second-line chemotherapy regimens were a combination of taxanes, ifosfamide and platinum in 49 cases (66%). Overall, 33 patients (28%) received third-line chemotherapy. A total of 88 patients (75%) underwent post-chemotherapy surgery. The 5-year overall survival for intermediate (n=50) and poor prognosis (n=67) was 89% and 83% (P=0.21), respectively. In poor prognosis patients, patients with two or more risk factors (any of high lactic dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin levels, and presence of non-pulmonary visceral metastases) had significantly worse survival than those with only one risk factor (71% and 91%, respectively, P=0.01).
ConclusionsThe 5-year overall survivals of poor-prognosis testicular non-seminomatous germ cell tumor patients reached 83%. Further stratification of poor-prognosis patients based on a number of risk factors has the potential to further identify those with poorer prognosis.

Web of Science ® 被引用回数 : 11

リンク情報
DOI
https://doi.org/10.1111/iju.12844
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/26094715
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000362456800008&DestApp=WOS_CPL

エクスポート
BibTeX RIS